Prevail Therapeutics Inc. — Form D
Prevail Therapeutics Inc. of NEW YORK, NY, a company, filed a Form D exempt-offering notice with the SEC on 2018-03-14. The offering totals $65.0M, of which $57.0M was reported sold. Industry: Other Health Care.
Offering
- Filed: 2018-03-14
- Form: D
- Accession: 0001714798-18-000002
- Industry: Other Health Care
- Exemptions: 06b
- Total offering: $65.0M
- Amount sold: $57.0M
- Remaining: $8.0M
- Investors: 15
- Date of first sale: 2018-03-07
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-307751
Issuer
- Name: Prevail Therapeutics Inc.
- CIK: 0001714798
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2017
- Address: 430 EAST 29TH STREET, SUITE 940, NEW YORK, NY, 10016
- Phone: 917-336-9310
Officers, directors & promoters (5)
| Name | Role | Location |
|---|
| ASA ABELIOVICH | Director | NEW YORK, NY |
| Mona Ashiya | Director | New York, NY |
| CARL GORDON | Director | SAN DIEGO, CA |
| Peter Thompson | Director | Chanhassen, MN |
| ASA ABELIOVICH | Executive Officer | NEW YORK, NY |
More